Stronger Together: Building a Leading Global Spine and Orthopedics Company

Forward-Looking Statements  This communication contains statements which, to the extent they are not statements of historical or present fact, constitute “forward-looking statements” under the securities laws. From time to time, oral or written forward-looking statements may also be included in other information released to the public. These forward-looking statements are intended to provide Orthofix’s and…

Orthofix Announces a Strategic Partnership Agreement with CGBio

Orthofix Medical and CGBio Announce Strategic Partnership Agreement for Novosis rhBMP-2 Bone Graft Solutions LEWISVILLE, Texas–(BUSINESS WIRE)– Orthofix Medical Inc. (NASDAQ:OFIX), a global medical device company with a spine and orthopedics focus, today announced a strategic partnership agreement with CGBio, a developer of innovative, synthetic bone grafts currently used clinically in Asia for spine, orthopedic, trauma…

FDA Approves AccelStim Bone Healing Therapy Device and Expands Orthofix’s Portfolio of Bone Growth Stimulation Solutions

LEWISVILLE, Texas–(BUSINESS WIRE)– Orthofix Medical Inc. (NASDAQ:OFIX), a global medical device company with a spine and orthopedics focus, today announced the U.S. Food and Drug Administration (FDA) pre-market approval for the AccelStim™ bone healing therapy Class III device. The AccelStim device provides a safe and effective nonsurgical treatment for indicated fresh fractures and for fractures that have not…